2009

1. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

   Multiple Sclerosis, Vol. 15, Núm. 2, pp. 219-228